A total of 143 patients with schizophrenia, who ranged from 28 to 42 years old, were studied. Of these, 68 patients were running a continuously progredient course, 75 were in the phase of exacerbation of the attack-like progredient course of schizophrenia. Group I (n = 76) of patients received the enterosorbent polysorb and a complex of antioxidants (tocoferolum acetatum, ascorbic acid, quercetin) as a supplement to the conventional therapy, group II (n = 67) was placed on the conventional therapy only. A complex of the antioxidants as well as the enterosorbent had a positive effect on the clinical course of the condition in 63.2% of group I patients who managed, among other therapeutic benefits, to achieve a stable remission. They have also demonstrated a concomitant improvement or normalization of indices for lipid peroxidation.